Imexpharm Corp Cash Flow-to-Debt Ratio
Imexpharm Corp cash flow-to-debt ratio. Imexpharm Corp (IMP) has a Cash Flow-to-Debt Ratio of 0.09x as of June 2026, meaning its operating cash flow of ₫55.75 Billion could theoretically repay 0% of its total liabilities (₫605.60 Billion) in one year. Check how aggressively does Imexpharm Corp reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Imexpharm Corp (2019–2025)
Cash flow-to-debt ratio of Imexpharm Corp from 2019 to 2025. Historical debt coverage capacity for Imexpharm Corp across 7 annual periods. Check cash flow quality index of Imexpharm Corp to evaluate the quality of earnings relative to operating cash generation.
Imexpharm Corp Cash Flow-to-Debt Ratio by Year (2019–2025)
Imexpharm Corp cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Imexpharm Corp. For the full cash flow conversion analysis, see Imexpharm Corp (IMP) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (VND) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | ₫54.17 Billion | ₫476.11 Billion | ▼ -83.1% |
| 2024 | 0.67x | ₫216.27 Billion | ₫321.66 Billion | ▲ +611.7% |
| 2023 | -0.13x | ₫-40.47 Billion | ₫308.04 Billion | ▼ -113.3% |
| 2022 | 0.99x | ₫378.60 Billion | ₫382.50 Billion | ▲ +110.8% |
| 2021 | 0.47x | ₫234.88 Billion | ₫500.29 Billion | ▲ +134.9% |
| 2020 | 0.20x | ₫73.15 Billion | ₫365.97 Billion | ▼ -13.5% |
| 2019 | 0.23x | ₫66.59 Billion | ₫288.29 Billion | — |